Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group RecommendationsMark S. Freedman, E. Ann Yeh, Virginia Devonshire et al.|Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques|2020Cited by 133
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
Bradykinin B<sub>1</sub>receptor expression and function on T lymphocytes in active multiple sclerosisAlexandre Prat, Jack P. Antel, L. Weinrib et al.|Neurology|1999Cited by 62